Thalassemia Market
Summary
Thalassemia is a hereditary blood disorder in which a person’s body makes an abnormal form of hemoglobin, which is the protein molecule in red blood cells (RBCs), which carries oxygen. The disorder results in unwarranted damage of red blood cells, which leads to anemia. Anemia is a condition in which the body doesn’t have adequate amount of normal and healthy red blood cells. There are majorly two types of thalassemia based on these proteins known as the Alpha thalassemia and the Beta thalassemia. There is also a third type viz. Sickle beta thalassemia, which is like a combination of sickle cell disease and beta thalassemia.
Click here for sample report @ http://www.wiseguyreports.com/sample-request/1615781-global-thalassemia-market-report-2016-edition
Report Highlights
Even though it is a rare genetic disorder, the number of people affected by it has been growing with time. While those with thalassemia minor have hardly any threat to their life and only require occasional blood transfusion to sustain, thalassemia major patients need to go for periodic transfusions for a sustained life. In case of infants, thalassemia major often leads to still birth or cause death shortly after the baby’s birth. Presently the only cure for thalassemia is a bone marrow transplantation therapy, which is done mostly for severe cases of thalassemia.
The key factors which are anticipated to drive this market include rising healthcare expenditure, rising spending on stem cell therapy research and development and rising population in the East-Asia and Pacific region of the world. Some of the noteworthy developments of this industry include the advances in the iron chelation therapy, development of gene therapy and fetal hemoglobin inducers as potential curatives for thalassemia. However, the growth of respective industry is challenged by the high cost of treatments, lack of alternative treatments and unmet market of the Asia-Pacific.
Table of Contents
1.2 Types of Thalassemia
1.2.1 Alpha Thalassemia
1.2.2 Beta Thalassemia
1.2.3 Sickle Beta Thalassemia
1.3 Signs and Symptoms
1.4 Treatment Options
1.4.1 Blood Transfusion
1.4.2 Bone Marrow Transplant
2.2 Global Thalassemia Diagnosis by Category
2.3 Global Transfusion-Dependent β Thalassemia by Region
2.4 Global Thalassemia Market by Therapy
2.4.1 Global Bone Marrow Transplant Revenue
2.4.2 Global LentiGlobin BB305 Revenue
2.4.3 Global Luspatercept Revenue
3.1.1 The US β Thalassemia Carrier Patient Population
3.1.2 The US β Thalassemia Major Patient Population
3.1.3 The US Transfusion-Dependent β Thalassemia Patients
3.1.4 The US β Thalassemia Sibling-Matched Stem Cell Transplant
.Continued
For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/1615781-global-thalassemia-market-report-2016-edition
About Us
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.
Contact Us:
NORAH TRENT
Partner Relations & Marketing Manager
sales@wiseguyreports.com
www.wiseguyreports.com
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
Summary
Thalassemia is a hereditary blood disorder in which a person’s body makes an abnormal form of hemoglobin, which is the protein molecule in red blood cells (RBCs), which carries oxygen. The disorder results in unwarranted damage of red blood cells, which leads to anemia. Anemia is a condition in which the body doesn’t have adequate amount of normal and healthy red blood cells. There are majorly two types of thalassemia based on these proteins known as the Alpha thalassemia and the Beta thalassemia. There is also a third type viz. Sickle beta thalassemia, which is like a combination of sickle cell disease and beta thalassemia.
Click here for sample report @ http://www.wiseguyreports.com/sample-request/1615781-global-thalassemia-market-report-2016-edition
Report Highlights
Even though it is a rare genetic disorder, the number of people affected by it has been growing with time. While those with thalassemia minor have hardly any threat to their life and only require occasional blood transfusion to sustain, thalassemia major patients need to go for periodic transfusions for a sustained life. In case of infants, thalassemia major often leads to still birth or cause death shortly after the baby’s birth. Presently the only cure for thalassemia is a bone marrow transplantation therapy, which is done mostly for severe cases of thalassemia.
The key factors which are anticipated to drive this market include rising healthcare expenditure, rising spending on stem cell therapy research and development and rising population in the East-Asia and Pacific region of the world. Some of the noteworthy developments of this industry include the advances in the iron chelation therapy, development of gene therapy and fetal hemoglobin inducers as potential curatives for thalassemia. However, the growth of respective industry is challenged by the high cost of treatments, lack of alternative treatments and unmet market of the Asia-Pacific.
Table of Contents
- Overview
1.2 Types of Thalassemia
1.2.1 Alpha Thalassemia
1.2.2 Beta Thalassemia
1.2.3 Sickle Beta Thalassemia
1.3 Signs and Symptoms
1.4 Treatment Options
1.4.1 Blood Transfusion
1.4.2 Bone Marrow Transplant
- Global Thalassemia Market
2.2 Global Thalassemia Diagnosis by Category
2.3 Global Transfusion-Dependent β Thalassemia by Region
2.4 Global Thalassemia Market by Therapy
2.4.1 Global Bone Marrow Transplant Revenue
2.4.2 Global LentiGlobin BB305 Revenue
2.4.3 Global Luspatercept Revenue
- Regional Analysis
3.1.1 The US β Thalassemia Carrier Patient Population
3.1.2 The US β Thalassemia Major Patient Population
3.1.3 The US Transfusion-Dependent β Thalassemia Patients
3.1.4 The US β Thalassemia Sibling-Matched Stem Cell Transplant
.Continued
For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/1615781-global-thalassemia-market-report-2016-edition
About Us
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.
Contact Us:
NORAH TRENT
Partner Relations & Marketing Manager
sales@wiseguyreports.com
www.wiseguyreports.com
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
